WuXi AppTec has been granted a patent for macrocyclic compounds designed for pharmaceutical applications, specifically for treating cancer associated with farnesylated proteins. The patent includes methods for preparing these compounds and their pharmaceutical compositions. GlobalData’s report on WuXi AppTec gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on WuXi AppTec, AI-assisted drug screening was a key innovation area identified from patents. WuXi AppTec's grant share as of June 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12018011B2 encompasses a series of claims related to novel compounds characterized by specific chemical formulas, particularly those represented by Formula (II) and its derivatives. The claims detail various structural features of these compounds, including the presence of specific functional groups and substituents, such as halogens, alkyl groups, and nitrogen-containing moieties. The compounds are designed to exhibit a range of molecular weights, with stipulations that they should not exceed 1,000 g/mol, and may exist in various stereoisomeric forms, including racemates and single enantiomers. Additionally, the patent outlines the potential for these compounds to be formulated into pharmaceutical compositions, which include a pharmaceutically acceptable carrier, excipient, or diluent.
The patent further specifies that the compounds may be utilized in various therapeutic applications, with particular emphasis on their pharmacological properties. The claims also highlight the versatility of the compounds, allowing for modifications that can enhance their efficacy or alter their pharmacokinetic profiles. The detailed structural variations and the potential for diverse applications underscore the innovative nature of the compounds covered by this patent, positioning them as significant candidates for further research and development in the pharmaceutical field.
To know more about GlobalData’s detailed insights on WuXi AppTec, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
